BCR/ABL1, Tyrosine Kinase Inhibitor Resistance, Kinase Domain Mutation Screen, Sanger Sequencing Build info

Synonyms

• BCR/ABL1 TYROSINE SEQ
• LAB11201

Short Name

BCR/ABL1 TYROSINE SEQ

Procedure Master Number

LAB11201

Procedure ID

114778

Clinical Info

Evaluating patients with chronic myelogenous leukemia and Philadelphia chromosome positive B-cell acute lymphoblastic leukemia receiving tyrosine kinase inhibitor (TKI) therapy, who are apparently failing treatment
Preferred initial test to identify the presence of acquired BCR-ABL1 mutations associated with TKI-resistance.

Specimen Type

Blood, Bone Marrow

Container

Collection Instructions

Container/Tube: Lavender(EDTA) Top Tube
Specimen: 10 mL Whole Blood (8 mL min) or 4 mL Bone marrow (2mL min)
Transport temperature: Refrigerated
Note: Refrigerated specimens must arrive within 5 days of collection, and ambient specimens must arrive within 3 days (72 hours) of collection.
The following information is required:
1. Patient's fusion type (p210, p190, p205 or p230)
2. Pertinent clinical history
3. Clinical or morphologic suspicion
4. Specimen source (blood or bone marrow)

Transport Instructions

Specimen Stability

3 Days Room Temperature
5 Days Refrigerated
Unacceptable Frozen

Methodology

Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Sanger Sequencing

Days Performed

TAT: 6-8 Days
If BCR/ABL1 fusion type (p210, p190, p205 or p230) is not provided, BADX / BCR/ABL1, Qualitative, Diagnostic Assay, Varies will be performed at an additional charge.
In the event that no fusion form (p190, p205, p210, p230) is identified by qualitative testing, this test will be canceled.

Performing Laboratory

Mayo Medical Laboratories

CPT

81170
LOINC Code: 55135-8

PDM

235768

Results